ideasIdea
A dedicated programme for cachexia and treatment toxicity research
Wasting and side-effects kill or stop treatment for a large share of patients but attract almost no dedicated funding. This would create a standing programme for them.
A programme with its own review panel funds cachexia mechanisms (GDF15, inflammatory and neural circuits), interventional trials of anti-cachexia agents and nutrition and exercise bundles, and toxicity science (neuropathy, cardiotoxicity, cytopenias, cognitive effects) with biomarkers and prevention trials. Supportive-care research fails in general panels because it is judged as less innovative; a dedicated pot and reviewers who know the field fixes that. GDF15 antagonists reaching late-phase trials show the biology is tractable.
Hypothesis
A dedicated programme at 2% of a national budget doubles registered interventional trials in cachexia and toxicity within five years and yields at least one approved supportive-care agent or validated toxicity-prevention strategy within ten.
Rationale
Cachexia is implicated in up to a third of cancer deaths; the recent progress on GDF15 came from industry, not academia, because academic supportive-care research was starved. Dedicated programmes created fields in palliative care in the UK and in geriatric oncology in France.
What would test it
Portfolio audit, then launch and compare trial registrations, publications and industry co-investment in the supported area after five years with a matched neglected area.
Maturity
speculative
Who has to act
philanthropy
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.
- Cachexia, toxicity and the limits of the patient · Patients often die of wasting or cannot tolerate the doses that would work. Treating the patient, not just the tumour, lags far behind.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.